JP2017057199A5 - - Google Patents

Download PDF

Info

Publication number
JP2017057199A5
JP2017057199A5 JP2016178997A JP2016178997A JP2017057199A5 JP 2017057199 A5 JP2017057199 A5 JP 2017057199A5 JP 2016178997 A JP2016178997 A JP 2016178997A JP 2016178997 A JP2016178997 A JP 2016178997A JP 2017057199 A5 JP2017057199 A5 JP 2017057199A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
agent according
preventive
polyethylene glycol
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016178997A
Other languages
English (en)
Japanese (ja)
Other versions
JP6639364B2 (ja
JP2017057199A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017057199A publication Critical patent/JP2017057199A/ja
Publication of JP2017057199A5 publication Critical patent/JP2017057199A5/ja
Application granted granted Critical
Publication of JP6639364B2 publication Critical patent/JP6639364B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016178997A 2015-09-18 2016-09-13 角膜真菌症の予防または治療剤 Expired - Fee Related JP6639364B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562220847P 2015-09-18 2015-09-18
US62/220,847 2015-09-18

Publications (3)

Publication Number Publication Date
JP2017057199A JP2017057199A (ja) 2017-03-23
JP2017057199A5 true JP2017057199A5 (https=) 2019-09-05
JP6639364B2 JP6639364B2 (ja) 2020-02-05

Family

ID=58288799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016178997A Expired - Fee Related JP6639364B2 (ja) 2015-09-18 2016-09-13 角膜真菌症の予防または治療剤

Country Status (13)

Country Link
US (1) US10166217B2 (https=)
EP (1) EP3351244A4 (https=)
JP (1) JP6639364B2 (https=)
KR (1) KR20180053340A (https=)
CN (1) CN108025000A (https=)
BR (1) BR112018005305A2 (https=)
HK (2) HK1256969A1 (https=)
MX (1) MX393608B (https=)
MY (1) MY183906A (https=)
PH (1) PH12018500579A1 (https=)
SG (1) SG11201802091RA (https=)
TW (1) TWI721015B (https=)
WO (1) WO2017047597A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112957321B (zh) * 2021-03-04 2022-08-05 青岛大学附属医院 一种氧化硫酸软骨素改性的那他霉素滴眼液及其制备方法
CN114568490B (zh) * 2022-04-01 2023-12-19 眉山职业技术学院(眉山技师学院) 雷帕霉素在抑制柑橘青霉菌生长中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
ES2507078T3 (es) * 2007-08-16 2014-10-14 Santen Pharmaceutical Co., Ltd Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad

Similar Documents

Publication Publication Date Title
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
FI3593817T3 (fi) Koostumus käytettäväksi likinäköisyyden ehkäisyssä tai vähentämisessä
WO2016064082A3 (ko) 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
WO2018022815A3 (en) Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug
WO2015120110A3 (en) Novel pharmaceutical formulations
JP2015078230A5 (https=)
EA201991299A1 (ru) Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
EA201692388A1 (ru) Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
HUE052332T2 (hu) Heteroaril-származék vagy gyógyászatilag elfogadható sója, eljárás annak elõállítására, és az ezeket hatóanyagént tartalmazó gyógyászati készítmény PI3 kinázokkal összefüggõ betegségek megelõzésére vagy kezelésére
JP2015007136A5 (https=)
EP4650370A3 (en) Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
CN109689652A (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
HRP20241716T1 (hr) Postupci liječenja promjena u ponašanju
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
JP2018021060A5 (https=)
JOP20170148A1 (ar) مثبطات Wnt لعلاج التليف
JP2017057199A5 (https=)
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
JP2016175884A5 (https=)
EA201991817A1 (ru) Интраназальная композиция, включающая бетагистин